Everyone you sell your product or service to is a customer. However, the question is: do you treat them as a business or a consumer? You might think that’s a pointless distinction since your goal is simply to sell your product, right? Wrong. That question determines your product’s market fit. To illustrate, let’s define a consumer as someone who buys for non-monetary benefits, such as an experience or, in the case of this book, knowledge. No one buys a video game expecting to profit from it. No one buys a plane ticket to make money if they’re on vacation; a consumer’s satisfaction is whether the money was worth the experience. A business, however, will have two definitions; the first is the obvious definition: an organization or person who expects payment for services rendered. The second definition will be more pertinent to my thesis: an organization or person who expects to make more money than was spent on the purchase of your product or service. Using the plane ticket example: if I’m flying for work, I’m not flying for the experience; I’m flying to make money; I would not fly if the plane ticket costs more than what I’m getting back for doing my job. In that case, the airline isn’t selling to me as a consumer; it’s selling to me as a business. What matters is whether you view your customer as a consumer or a business. That determines how you approach them, your sales pitch, and how you assess the market fit of your product.
There are two common sales models: business-to-consumer (B2C) and business-to-business (B2B). You don’t need to be the first business (B1); you can be the second business (B2). But the fact remains B2 needs to make more money from their customer than they spend on B1.
In traditional business models, the buyer and the consumer are the same person; in medicine and education, they are often separate, in which the buyer is a business or should be seen as one. This distinction changes the rules in addressing market fit for such products.
EndeavorRx was developed by Akili Interactive Labs as a video game to treat ADHD. It gained FDA approval on June 15, 2020. The FDA had to create a new classification when EndeavorRx was approved. EndeavorRx works by utilizing skills people with ADHD are deficient in; it has an algorithm that can adjust the difficulty so that it’s not too hard but not too easy. The goal was to make you focus just enough so that it strains your brain but also makes it achievable, similar to doing sets at the gym: go too light, you don’t tear your muscles, but go too heavy, you don’t get any reps in, and you won’t tear your muscles either. The tearing is the goal of the workout because your muscles rebuild themselves in the coming days. The brain does something similar with its synapses via a process called synaptic pruning, also known as neuroplasticity. As you use the synapses that are normally weak in an ADHD brain, your brain strengthens those synapses, alleviating ADHD symptoms. A study showed even after a four-week break, the benefits of completing a full treatment of EndeavorRx did not significantly fade. Long-term benefit maintenance wasn’t studied, but if those synapses are not used regularly, they can weaken, so we would assume periodic maintenance with EndeavorRx is at least needed unless the patient consistently uses those synapses in their everyday lives, which they should if the treatment worked.
In early 2022, Akili Interactive Labs went public via a SPAC (Special purpose acquisition company) with Social Capital Suvretta Holdings Corp. I, and was (over)valued at $1 billion. After that, its value tanked until its acquisition by Virtual Therapeutics for $34 million in July of 2024; needless to say, the people who invested in Akili Interactive Labs, especially those after Series A funding, were not pleased. By Zero to One’s thesis, EndeavorRx should have been commercially successful: it was a technological and medical breakthrough; ADHD will always be around, so the market is durable; it was at least 10x better than the closest substitute: 35% to 60% discontinue their ADHD medication within a year due to not wanting to be on drugs or disliking the side effects, meaning the closest substitute was no treatment for many people; it had a great team behind it because they developed the game and secured FDA approval. EndeavorRx was also an app-based video game, so as long as their servers could handle mass adoption, distribution and scalability are easily achieved. What went wrong? Zero to One’s thesis only works if the buyer and consumer are the same person; with EndeavorRx, they were separate people. When the consumer and buyer are separate people, you have to look at the economics of the buyer to scale. Akili Interactive Labs tried charging insurance companies $540 for 3 months and $300 for 3 months out of pocket. By contrast, generic Adderall costs between $10 to $30 a month. At first glance, it makes no sense why insurance companies wouldn’t cover a permanent solution for an upfront cost. However, health insurance companies have a high client turnover rate from switching jobs and non-renewed contracts. In other words, the cost would be greater than the existing solution. Why would anyone pay repeatedly to reap the benefits of Endeavor? Even if it was a one-time purchase, EndeavorRx had another problem: it needs to be consistently used. It sounds like not much of an issue because people with ADHD play video games all the time. The problem was that many people reported Endeavor was not a fun video game to play; it was a chore to play consistently to reap the benefits, especially for the group they’re trying to reach and treat: people with ADHD. Albeit, the chore of playing could have been due to regulations. That said, EndeavorRx is still better than the alternative for those who couldn’t tolerate their ADHD medication side effects.
Facing the insurer roadblock, Akili Interactive Labs launched EndeavorOTC, an over-the-counter version of EndeavorRx that doesn’t rely on insurance companies, in June of 2023. Currently, its options are $24.99 for a single month, $16.66 for 6 months ($99.99), or $10.83 for 12 months ($130). Not surprisingly, they couldn’t successfully market EndeavorOTC even with a B2C model since it was still a chore to play. In 2024, Akili Interactive Labs generated $1.94 million in revenue.
You might wonder why Virtual Therapeutics acquired Akili Interactive Labs. There are many reasons why. One could be that they wanted access to Akili Lab’s proprietary products or they wanted the game or they saw some other non-monetary benefit from acquiring Akili Lab at a steep discount.
Another tech startup, Cognoa, developed an AI app called Canvas Dx to allow primary care pediatricians to diagnose autism at the point-of-care (POC), bypassing a 6- to 18-month waitlist to see a specialist; Canvas Dx received FDA approval in June of 2021. Given the waitlist, you would think health insurance companies have nothing to gain by covering Canvas Dx due to the high turnover rate previously discussed with EndeavorRx, but in January of 2024, Highmark Blue Cross Blue Shield agreed to cover the cost of Canvas Dx; Wyoming Medicaid started covering Canvas Dx starting July 1, 2024; sometime in late 2024, Orange County launched a pilot program to improve autism diagnosis with Canvas Dx included. All of these insurers cover Canvas Dx without prior authorization. Why is Canvas Dx making progress towards coverage without prior authorization while EndeavorRx failed? There were hidden costs related to undiagnosed autism that led to ER visits that ultimately cost insurance companies more than the cost of paying for Canvas Dx’s use. A study titled “Increased delay from initial concern to diagnosis of autism spectrum disorder and associated health care resource utilization and cost among children aged younger than 6 years in the United States” (PMID: 36989447) found that children with longer than the median time till diagnosis cost health insurance companies over $5,000 per child. Even though insurance companies have a high client turnover, they’re still picking up kids that are on the waitlist to see a specialist; it’s cheaper just to pay for Canvas Dx’s use, and unlike EndeavorRx, Canvas Dx is a one-time use product per child. It can cost anywhere between $2,500 to $5,000 to get assessed by a specialist; even if a child tests negative, it saves insurers money. Regardless of whether a child truly has autism, it is fiscally attractive for insurers to cover the use of Canvas Dx; every use of Canvas Dx is not simply money spent; it is also money saved. Unlike EndeavorRx, Canvas Dx outperforms traditional methods, satisfying Zero to One’s criteria, has a viable flow of money, and has a satisfactory customer experience, satisfying It’s Not About The Money, Until It Is’s criteria.
Prior authorizations are used by health insurance companies to manage expensive medication and treatment. With Canvas Dx’s use case, a prior authorization was completely pointless since it would cost health insurance companies more money. Autism assessments are a bit subjective due to human judgment that is naturally involved with ABA. Canvas Dx standardizes this to provide integrity that helps to minimize fraud, waste, and abuse, making it extremely attractive to insurers from a business standpoint.
Apart from meeting the economic criteria that EndeavorRx did not, Canvas Dx was not a chore to use; parents only use it once. Canvas Dx was designed to be user-friendly. While some users may report difficulty uploading their videos and the app crashing, it is still a one-time use for parents and won’t be a chore to use consistently like EndeavorRx was.
Because of this, Cognoa is steadily growing. Is it as fast as it could be with a viral product? No. But it’s also building its brand. In April of 2026, Cognoa partnered with Catalight, a social enterprise that focuses on getting autistic children faster treatment. Cognoa originally had an autism therapeutic AI on their roadmap but that idea is on hold, at least for now, to focus on the autism diagnosis market. Catalight serves 49 states and is one of the largest nonprofits in the nation, having generated almost $400 million in revenue for the fiscal year of 2025. Catalight’s mission is to reduce health disparities and inequities. Girls and non-white people with autism tend to be diagnosed later in life; Catalight wants to fight this inequity. Cognoa trained Canvas Dx using data from multiple ethnicities and girls to ensure it can account for slight differences in behavioral phenotype. This made Cognoa a very attractive partner for Catalight to further their mission. In return, Cognoa gains access to Catalight’s vast network of insurers to expand coverage for Canvas Dx.
Despite being a groundbreaking creation, EndeavorRx fell short in both the user experience for the patient, the consumer, and for insurers, the business, in creating an ROI. Conversely, Canvas Dx was successful in selling to insurers for its ROI and better experience for patients and pediatricians, the consumers. Even if EndeavorRx managed to fix all of its internal issues, it still would have flopped commercially because it failed to generate an ROI for its buyer, whereas Canvas Dx is doing well commercially despite having its own frictions because it saves insurers money with each use.
This article is an excerpt from a book I am writing about the economics of innovation and creating change.
Disclaimer: The current CEO of Cognoa is my mentor.